Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL

MAb’s CAR-T Like Efficacy Seen Giving Wide Adoption

Lymphoma
MorphoSys, Incyte to co-commercialize Monjuvi in the US • Source: Shutterstock

More from New Products

More from Scrip